Tag: Biomarkers

3
Jun 2016

Bionest

Some Thoughts on the Latest Immuno-oncology Approval

On May 18, the U.S. Food and Drug Administration approved the latest immunotherapeutic drug, atezolizumab (Tecentriq), from Roche’s California division, Genentech. The drug, a PD-L1 inhibitor, is the first product in its class to gain approval for a common form of bladder cancer, urothelial carcinoma — specifically for patients with advanced disease or those who...
27
May 2016

Bionest

See you at ASCO 2016!

It’s nearly June, which means one thing for the Bionest Oncology team:  ASCO is right around the corner.  As we gear up for our time in Chicago, we are taking a look at some of the big topics and anticipated data we expect to see during the conference. The theme of ASCO this year is...
21
Jan 2016

Bionest

Increasing Role for Biomarkers in R&D, Clinical Medicine, and Pharma Marketing

Bionest team member Rachel Laing recently contributed to a feature in the January issue of PharmaVoice on the growing role and prominence of biomarker strategies in drug development and commercialization. In addition to helping to better identify those patients who will respond to a particular therapy, a biomarker strategy enables companies to differentiate their product and...